Price
CHART BY
Frequently asked questions
What is Revolution's market capitalization?
The market capitalization of Revolution is $43.68B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Revolution?
Revolution's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$8.815. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Revolution's stock?
Currently, 22 analysts cover Revolution's stock, with a consensus target price of $251.39. Analyst ratings provide insights into the stock's expected performance.
What is the EBITDA for Revolution?
Revolution's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$1.61B. EBITDA measures the company's overall financial performance.
What is the free cash flow of Revolution?
Revolution has a free cash flow of -$1.23B. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Revolution have, and what sector and industry does it belong to?
Revolution employs approximately 883 people. It operates in the Health Care sector, specifically within the Other Pharmaceuticals industry.
What is the free float of Revolution's shares?
The free float of Revolution is 193.01M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $43.68B
- EPS (TTM)
- -$8.815
- Free Float
- 193.01M
- EBITDA (TTM)
- -$1.61B
- Free Cashflow (TTM)
- -$1.23B
Pricing
- 1D span
- $198.07$207.44
- 52W span
- $42.18$224.24
Analyst Ratings
The price target is $251.39 and the stock is covered by 22 analysts.
Buy
21
Hold
1
Sell
0
Information
Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.
- Employees
- 883
- Industries
- Other Pharmaceuticals
- Sector
- Health Care
Identifier
- Primary Ticker
- RVMD
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet